Tadalafil Tablet
Product Images NDC 71335-2626

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-2626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure of tadalafil. The diagram shows the molecular framework including fused ring systems and functional groups characteristic of tadalafil's chemical makeup.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs showing the difference in blood pressure (mmHg) between tadalafil and placebo over time (hours). The charts compare Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, with measurements taken across multiple time points up to 96 hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs depicting changes in systolic blood pressure (mmHg) over 24 hours post-dose for Tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg. The upper graph shows standing systolic blood pressure, and the lower graph shows supine systolic blood pressure, measured at various time points up to 24 hours.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

Line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of tadalafil or placebo combined with doxazosin. The x-axis shows time after administration, and the y-axis shows systolic blood pressure changes. Four groups are represented: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following five consecutive days of administration. The graph depicts concentration decreasing over time with error bars for each data point.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

Line graph showing change from baseline in IPSS total score over 12 weeks of treatment. The graph compares tadalafil tablets 5 mg to placebo, with tadalafil showing a greater decrease in IPSS score indicating improvement. Data points are plotted at 0, 4, 8, and 12 weeks, with a significant difference (p<0.01) at week 12.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil tablets 5 mg and placebo. The y-axis represents the change from baseline, and the x-axis shows treatment duration in weeks. Tadalafil shows a greater decreasing trend in IPSS scores compared to placebo, with statistically significant differences indicated.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph comparing least-squares mean change from baseline over 26 weeks of therapy between Tadalafil/Finasteride and Placebo/Finasteride treatment groups. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows LS mean change from baseline with values ranging from 0 to -7. Data points include treatment differences with statistical significance annotations.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between tadalafil 5 mg tablets and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change from baseline score. The graph shows greater score improvement with tadalafil than placebo over time, with statistical significance noted at 12 weeks (p<0.01).*

FDA Label Image

Label (Lbl713352626)

Label for Tadalafil Tablets USP 10 mg oral tablets. Package contains 30 tablets. The label includes the NDC 71335-2626-1, states the tablets are repackaged by Bryant Ranch Prepack, Inc. in Burbank, CA, and manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. Storage instructions and a warning to keep out of reach of children are included, along with a note not to split tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.